• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
  • Home
  • Newsroom
  • Media Center

Media Center

Corporate Slide Deck

Corporate Slide deck

Allogeneic Vs. Autologous Fact Sheet

Allogeneic vs. Autologous Fact Sheet

What is NKG2D?

NKG2D Fact Sheet

Multiplexing shRNA Fact Sheet

Multiplexing shRNA Fact Sheet

shRNA Fact Sheet

shRNA Fact Sheet

Dual targeting: what for?

Dual CAR Fact Sheet

What is B7-H6?

B7-H6 Fact Sheet

What is TIM Technology?

TIM Fact Sheet

CAR T vs NK Cells

CAR T vs NK Cells

Hairpins and Scissors – Delivering a Non-Gene Edited Allogeneic CAR T Cell Therapy for the Masses White Paper (2020)

White Paper

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process White Paper (2019)

White Paper

CAR T NKR-2: Leveraging the Breadth of Innate Immunity White Paper (2017)

White Paper

Celyad Oncology Logo

Load More

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use